Olympio Metals Limited (ASX:OLY) Announces Sale of Halls Creek Tenements
Olympio Metals (ASX:OLY) enters option agreement to sell Halls Creek tenements, focusing on its Canadian Dufay Cu-Au Project.
Tag: Corporate Strategy & Guidance
HealthCo Healthcare & Wellness REIT (ASX:HCW) Announces 1H FY25 Results
HealthCo Healthcare & Wellness REIT (ASX:HCW) reports a 5% growth in FFO/unit and DPU for 1H FY25, reaffirming its FY25 guidance.
Cochlear Limited (ASX:COH) Announces Half-Year 2024 Financial Results
Cochlear Limited (ASX:COH) reports a 5% revenue increase and an 8% interim dividend rise for the half year ended December 2024.
Desane Group Holdings Limited (ASX:DGH) Extends Lease with Brisbane City Council
Desane Group Holdings Limited (ASX:DGH) extends lease with Brisbane City Council until 2030, securing $4.5 million in rental income.
Micro-X Ltd (ASX:MX1) Secures $6.0M Contract Extension with US DHS
Micro-X Ltd (ASX:MX1) secures a $6.0M contract extension with US DHS to advance airport security checkpoint projects.
VHM Limited (ASX:VHM) Announces Staged Expansion to Critical Minerals Production
VHM Limited (ASX:VHM) announces a staged expansion of its Goschen Project, aiming for first production in two years with significant financial metrics.
Krakatoa Resources Ltd (ASX:KTA) Advances Zopkhito Antimony-Gold Project
Krakatoa Resources Ltd (ASX:KTA) advances its Zopkhito Antimony-Gold Project with significant resource estimates and plans for development by 2025.
Golden Cross Resources Ltd (ASX:GCR) Commences Gravity Surveys at Copper Hill Project
Golden Cross Resources Ltd (ASX:GCR) has commenced gravity surveys at its Copper Hill project, enhancing exploration data and supporting resource development.
Althea Group Holdings (ASX:AGH) Revises FY25 Financial Guidance
Althea Group Holdings (ASX:AGH) revises its FY25 revenue guidance to $26-$33 million and adjusts EBITDA expectations amidst strategic restructuring.
Neurotech International Ltd (ASX:NTI) Signs Development Agreement for Cannabinoid Therapies
Neurotech International Ltd (ASX:NTI) signs a development agreement with RH Pharma to develop cannabinoid therapies for pediatric neurological disorders.